Get the Daily Brief
Latest Biotech News
Retrons repurposed for precise genome editing — new tools emerge
Researchers unveiled retron‑based gene‑editing platforms that use bacterial reverse transcriptases to synthesize donor single‑stranded DNA intracellularly, enabling precise insertion and editing...
FDA accepts IND based solely on human vascularized organoid efficacy data — first‑ever
Qureator announced that the FDA has cleared an IND for SillaJen’s BAL0891 combination based primarily on efficacy data generated with Qureator’s vascularized tumor immune microenvironment (vTIME)...
Regeneron halts 2seventy‑acquired CAR‑T bbT369 — program dropped
Regeneron confirmed it has stopped development of bbT369, a dual‑targeting CAR‑T therapy (CD79a/CD20) acquired through its 2024 purchase of 2seventy bio’s pipeline. The company halted the phase...
FDA reinstates GSK’s Blenrep — approval narrowed to Velcade combo
The FDA cleared GlaxoSmithKline’s BCMA-targeting antibody–drug conjugate Blenrep to return to the U.S. market with a restricted label. The agency approved Blenrep for use in combination with...
Moderna’s CMV vaccine fails Phase 3 — company halts most development
Moderna announced that its phase III trial of the mRNA‑1647 cytomegalovirus (CMV) vaccine missed its primary efficacy endpoints and will largely stop further development of the program. The...
Ventyx’s NLRP3 data: biomarker collapse and a market fever
Ventyx Biosciences reported Phase 2 data showing its oral NLRP3 inhibitor VTX3232 produced rapid, large reductions in inflammatory biomarkers in patients with obesity and cardiovascular risk...
10x, Roche and Prognosys sue Illumina: patent fight targets spatial and single‑cell tech
10x Genomics partnered with Roche Sequencing Solutions and Prognosys Biosciences to file twin lawsuits accusing Illumina of infringing nine patents tied to spatial transcriptomics and single‑cell...
Cellarity publishes cell‑state drug framework in Science — AI maps new discovery route
Cellarity published a manuscript in Science describing a framework that fuses transcriptomic datasets with AI modeling to discover ‘cell state‑correcting’ medicines. The company outlined methods...
Retrons repurposed for high‑precision editing — new toolset for large DNA fixes
Researchers reported new retron‑based gene‑editing technologies that use bacterial retrons to produce multicopy single‑stranded DNA templates inside cells, enabling precise replacement and...
Live embryo imaging raises questions about PGT‑A accuracy — de novo mitotic errors found
High‑resolution, light‑sheet live imaging of late‑stage human preimplantation embryos revealed de novo mitotic errors in trophectoderm cells that were not detectable at earlier stages, challenging...
Flagship debuts Expedition Medicines — $50M bet on covalent, quantum‑informed discovery
Flagship Pioneering launched Expedition Medicines with a $50 million commitment to develop covalent‑binding small molecules using generative AI, quantum chemistry and chemoproteomics. The new...
FDA accepts IND supported by organoid efficacy — first approval without animal POC
Qureator announced that the FDA approved an Investigational New Drug (IND) application based solely on efficacy data generated with its vascularized tumor organoid model (vTIME), marking the first...
Takeda wagers on Innovent’s oncology lineup — $1.2B upfront in $11.4B deal
Takeda agreed to a major licensing and co‑development transaction with Innovent Biologics that includes $1.2 billion in up‑front payments and potential total consideration up to $11.4 billion for...
Ventyx’s oral NLRP3 pill slashes inflammation — partner talks ignite
Ventyx Biosciences reported Phase 2 data showing its oral NLRP3 inhibitor VTX‑3232 produced rapid, large reductions in inflammatory biomarkers linked to cardiovascular risk. In a randomized,...
Moderna halts CMV program after pivotal miss
Moderna announced that its Phase III CMV vaccine, mRNA‑1647, missed the primary efficacy endpoint and the company will stop further development of the shot for most populations. The pivotal...
Alector’s GSK‑backed antibody misses Phase III — cuts follow
Alector disclosed that its GSK‑partnered antibody failed to meet co‑primary clinical endpoints in a Phase III dementia trial. The negative outcome prompted the company to stop development of the...
Takeda’s major oncology blitz: $11.4B Innovent deal lands
Takeda struck a landmark partnership to license up to three immuno‑oncology and ADC candidates from Innovent Biologics in a deal valued at $11.4 billion, including a $1.2 billion up‑front payment....
Regeneron halts dual‑target CAR‑T study — bbT369 program stopped
Regeneron ended clinical development of bbT369, a dual‑targeting CAR‑T acquired with 2seventy bio, and halted enrollment in the dose‑escalation lymphoma study before advancing to phase 2. The...
10x, Roche and Prognosys sue Illumina over spatial and single‑cell patents
10x Genomics joined Roche Sequencing Solutions and Prognosys Biosciences to file two federal lawsuits accusing Illumina of infringing nine patents tied to spatial transcriptomics and single‑cell...
Flagship debuts Expedition — $50M to chase covalent, AI‑driven drugs
Flagship Pioneering unveiled Expedition Medicines with a $50 million commitment to develop covalent‑binding small molecules using generative chemistry, quantum‑informed models and chemoproteomics....